• SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments
• SAVOR is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes patients at high risk for cardiovascular events
• Onglyza did not meet the primary efficacy endpoint of superiority to placebo
• In additional analyses, patients treated with Onglyza had improved glycemic control over two years
Trending Articles
More Pages to Explore .....